Clinical Trials Logo

Acute Lung Injury clinical trials

View clinical trials related to Acute Lung Injury.

Filter by:

NCT ID: NCT04350710 Recruiting - Clinical trials for Acute Respiratory Distress Syndrome

Description of Respiratory Mechanics in Patients With SARS-CoV-2 Associated ARDS

Start date: March 18, 2020
Phase:
Study type: Observational

The aim of this observationnal study is to describe respiratory mechanics and lung recruitement in patients with SARS-CoV-2 Associated Acute Respiratory Distress Syndrome who underwent invasive ventilation on endotracheal tube, admitted to the medical ICU of Angers university hospital . Statics measurements of respiratory system compliance were performed at 2 differents levels of PEEP (15 cmH2O and 5 cmH2O). The recruited volume is computed as the difference between the volume expired from PEEP 15 to 5 cmH2O and the volume predicted by compliance at PEEP 5 cmH2O . The recruitment-to-Inflation (R/I) ratio (i.e. the ratio between the recruited lung compliance and CRS at PEEP 5 cmH2O) is used to assess lung recruitability. A R/I ratio value higher than or equal to 0.5 was used to define highly recruiter patients.

NCT ID: NCT04349618 Recruiting - COVID19 Clinical Trials

Ultraprotective Ventilation Without Extracorporeal Circulation During COVID 19 Pneumonia

VT4COVID
Start date: April 15, 2020
Phase: N/A
Study type: Interventional

Mortality of COVID-19 pneumonia with acute respiratory distress syndrome (ARDS) is extremely high in preliminary reports amounting to 50-60%. Duration of mechanical ventilation in these patients appears to exceed standard duration of mechanical ventilation in non-COVID-19 ARDS patients, suggesting that COVID-19 patients may be particularly at risk for ventilator-induced lung injury. Treatment of COVID-19 ARDS patients is to date mainly supportive with protective mechanical ventilation (ventilation with low tidal volume (VT) i.e. 6 ml/kg of predicted body weight (PBW) and plateau pressure control below 30 cm H2O). Mechanical ventilation with VT reduction below 6 ml/kg PBW in ARDS may reduce alveolar strain, driving pressure and hence ventilator-induced lung injury. Investigators recently performed a multicenter pilot study on 34 moderately severe to severe ARDS patients. This study demonstrated that ultraprotective ventilation with ultra-low VT (≤4.2 ml/kg PBW) without extracorporeal circulation may be applied in approximately 2/3 of the patients, with a 4 cmH2O median reduction in driving pressure, at the price of transient episodes of severe acidosis in approximately 1/3 of the patients. Investigators hypothesized that ultraprotective ventilation without extracorporeal circulation may reduce the mortality at day-90 and increase the number of days free from mechanical ventilation (VFD) at day-60, as compared to protective ventilation.

NCT ID: NCT04337190 Recruiting - Clinical trials for Acute Respiratory Distress Syndrome

Impact of Angiotensin II Receptor Blockers Treatment in Patients With COVID 19 (COVID-ARA2)

COVID-ARA2
Start date: April 3, 2020
Phase:
Study type: Observational

The actual pandemic infection related to SARS-CoV2 results in viral pneumonitis (COVID-19), that may, in the more severe cases, lead the patients to the intensive care unit (ICU). The more frequent presentation is acute respiratory distress syndrome (ARDS). To penetrate cells, SARS-CoV2 uses Angioconvertase type 2 (ACE2) as a cellular entry receptor. ACE2 belong to the renin-angiotensin-aldosteron system (SRAA), and ACE2 levels are directly modified when SRAA inhibitors are administred to patients, and ACE2 level increases particularely with Angiotensin II Receptor blockers (ARA2) use. The aim of our study is to determine ACE2 level and activity in patients with SARSCoV2 infection admitted to the intensive care unit (ICU). COVID ARA2 is a propsective cohort of patient with blood sampling at the day of admission, day 3 and day 7.

NCT ID: NCT04331613 Recruiting - COVID-19 Clinical Trials

Safety and Efficacy of CAStem for Severe COVID-19 Associated With/Without ARDS

Start date: January 27, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

A phase1/2, open label, dose escalation, safety and early efficacy study of CAStem for the treatment of severe COVID-19 associated with or without ARDS.

NCT ID: NCT04321616 Recruiting - SARS-CoV Infection Clinical Trials

The Efficacy of Different Anti-viral Drugs in COVID 19 Infected Patients

Start date: March 28, 2020
Phase: Phase 2/Phase 3
Study type: Interventional

The (World Health Organization) WHO NOR- (Coronavirus infectious disease) COVID 19 study is a multi-centre, adaptive, randomized, open clinical trial to evaluate the safety and efficacy of hydroxychloroquine, remdesivir and standard of care in hospitalized adult patients diagnosed with COVID-19. This trial will follow the core WHO protocol but has additional efficacy, safety and explorative endpoints.

NCT ID: NCT04319965 Recruiting - Critical Illness Clinical Trials

Complications Related to Transpulmonary Thermodilution

COTRADIL
Start date: February 8, 2020
Phase:
Study type: Observational

The transpulmonary thermodilution is commonly used in patients with acute circulatory failure in the intensive care unit and for monitoring surgical patients at high risk. However, the incidence of complications and their risk factors in patients monitored by transpulmonary thermodilution has not been completely reported yet.

NCT ID: NCT04316884 Recruiting - COVID-19 Clinical Trials

Mechanisms for Organ Dysfunction in Covid-19

UMODCOVID19
Start date: March 12, 2020
Phase:
Study type: Observational

The study aims to investigate organ dysfunction and biomarkers in patients with suspected or verified COVID-19 during intensive care at Uppsala University Hospital.

NCT ID: NCT04296071 Recruiting - Clinical trials for Cardiopulmonary Bypass

Neutrophil Phenotypic Profiling and Acute Lung Injury in Patients After Cardiopulmonary Bypass (CPB)

Start date: October 14, 2022
Phase:
Study type: Observational

Acute lung injury (ALI) following cardiopulmonary bypass (CPB) is a serious complication, often prolonging the length of stay in ICU and potentially dealing to mortality. The objective of this study is to assess the mechanism of CPB-mediated acute lung injury in pediatric patients.

NCT ID: NCT04289324 Recruiting - Extreme Prematurity Clinical Trials

Open Lung Maneuvers During High Frequency Oscillatory Ventilation in Preterm Infants

OPEN4HFOV
Start date: February 25, 2020
Phase: N/A
Study type: Interventional

To assess whether stepwise oxygenation-guided lung recruitment at regular intervals reduces the oxygen saturation index (OSI = Mean Airway Pressure × Fraction of inspired Oxygen × 100 / peripheral Oxygen Saturation, OSI = MAPxFiO2x100/SpO2) averaged over high frequency oscillation ventilation (HFOV) time in extremely preterm infants.

NCT ID: NCT04262440 Recruiting - ARDS Clinical Trials

The Effect of Caloric Supplement in the Clinical Outcomes in Acute Lung Injury Patients

Start date: April 11, 2019
Phase:
Study type: Observational

The optimal amount caloric intake were still controversy in critically ill patients in literature. There were no significant outcome difference with different caloric intake in acute lung injury patients. In order to identify the optimal amount caloric intake in acute lung injury patients, we conduct a prospectively observational study to see whether the caloric differences influence hospital mortality.